Digestery
Longevity supplements › Metformin and Aging › Studies

Population study: cases vs controls

Study of 188983 older adults with diabetes: closer pill-taking went with lower death risk

Rea and colleagues · Cardiovascular diabetology · 2023

Original title: Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Higher adherence to diabetes drugs went with lower all-cause death risk in all clinical groups and ages except frail patients aged 85 and over. The benefit was smaller in frail patients.

The study at a glance

Type of study
Population study: cases vs controls
Who or what was studied
188,983 people · Adults aged 65 and over with type 2 diabetes in Lombardy, Italy, taking mostly metformin and other older drugs
What was tested
How closely people took their diabetes pills vs risk of death over up to 6 years (cases who died vs matched controls)
What it measured
The question itself: aging, frailty and death in people without diabetes
Who has a stake
Company stake
Authors report research projects funded by, and fees from, drug companies including Novartis, GSK, Roche, Amgen, BMS and Servier.
Journal
Cardiovascular diabetology, 2023
Source
PubMed record 36899347. This page is based on the abstract only.

How much this study counts

  • –Shows a link, not a cause. It compares people who already had the outcome with people who did not, and may rely on memory.
  • ✓Large: 188,983 people.
  • ✓Measured the question itself: aging, frailty and death in people without diabetes.
  • –Company stake: Authors report research projects funded by, and fees from, drug companies including Novartis, GSK, Roche, Amgen, BMS and Servier.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related disease

    1

    1 benefit

  2. Trials in people: other measures

    3

    2 no difference, 1 harm

  3. Trials in people: lab tests or safety

    6

    2 benefit, 2 mixed, 2 no difference

  4. Population studies

    8

    6 benefit, 2 no difference

    ↑ This study is the ringed dot

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    3

    2 benefit, 1 harm

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does metformin slow aging in people without diabetes?”

Not shown in people without diabetes.

Confidence: low. Based on 26 on-topic papers.

Read the full answer

Of the other 7 papers on the same step: 5 benefit, 2 no difference. This one found benefit. It agrees with most of them.

  • Open item for a person: Rea 2023 studies adherence to all diabetes drugs (mostly metformin), not metformin alone; kept relevant, but check it belongs in this topic.

Other papers on the same step

See all 26 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads differed. The reviewer checked the abstract and kept the first read. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.